A new method for scoring financial conflicts of interest

International Journal of Occupational and Environmental Health

Volumn 21, Issue 1, 2015, Pages 49-52

  Maharaj, S V M ^a  

^a Center for Research on Environmental Medicine   (United States)

Author keywords

Campaign contributions; Ethics; FCoIS; Industry or corporate funding; Instrument or scale; International organizations; Public health and policy; Scientific and medical journals and publishing; Scientific societies and professional associations

Indexed keywords

CONFLICT OF INTEREST; ECONOMICS; ENVIRONMENTAL HEALTH; ETHICS; FINANCIAL MANAGEMENT; INTERPERSONAL COMMUNICATION; OCCUPATIONAL HEALTH; PROCEDURES;

CONFLICT OF INTEREST; DISCLOSURE; ENVIRONMENTAL HEALTH; FINANCIAL SUPPORT; OCCUPATIONAL HEALTH;

EID: 84925132936     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: 10.1179/2049396714Y.0000000097     Document Type: Article

References (17)

1. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty principle and industry-sponsored research. Lancet. 2000;356:635–8.
2. Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome in randomized controlled drug trials. Fam Pract. 2001;18:565–8.
3. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials. JAMA. 2003;290:921–8.
4. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167–70.
5. Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004;170:477– 80.
6. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry. 2005;162:1957–60.
7. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 2006;333:782.
8. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug–drug comparisons: why some statins appear more efficacious than others. PLoS Med. 2007;4:e184.
9. Huss A, Egger M, Hug K, Huwiler-Muntener K, Roosli M. Source of funding and results of studies of health effects of mobile phone use: Systematic review of experimental studies. Environ Health Perspect. 2007;115:1–4.
10. Nieto A, Mazon A, Pamies R, Linana JJ, Lanuza A, Jimenez FO, et al. Adverse effects of inhaled corticosteroids in funded and nonfunded studies. Arch Intern Med. 2007;167:2047–53.
11. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–60.
12. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252–60.
13. Egilman D, Scout, Kol L, Hegg LA, Bohme SR. Manipulated data in Shell’s benzene historical exposure study. Int J Occup Environ Health. 2007;13:222–32.
14. Gallagher R. For shame, Merck and Elsevier. The Scientist. June 2009;23:13.
15. Ladou J, Teitelbaum DT, Egilman DS, Frank AL, Kramer SN, Huff J. American College of Occupational and Environmental Medicine (ACOEM): a professional association in service to industry. Int J Occup Environ Health. 2007;13:404–26.
16. Jacobson M. Lifting the veil of secrecy from industry funding of nonprofit health organizations. Int J Occup Environ Health. 2005;11:349–55.
17. Huff J. Industry influence on occupational and environmental public health. Int J Occup Environ Health. 2007;13:107–17.